Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PI3K Gene Mutation”

77 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 77 results

Early research (Phase 1)Study completedNCT05300048
What this trial is testing

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Who this might be right for
Advanced Solid TumorPIK3CA MutationPTEN Loss of Function Mutation
Faeth Therapeutics 34
Not applicableStudy completedNCT05054166
What this trial is testing

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Who this might be right for
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Zhejiang Cancer Hospital 14
Early research (Phase 1)Looking for participantsNCT05216432
What this trial is testing

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc. 930
Large-scale testing (Phase 3)UnknownNCT06249997
What this trial is testing

An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

Who this might be right for
APDS Gene Mutation
Pharming Technologies B.V. 3
Testing effectiveness (Phase 2)Looking for participantsNCT06463028
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Who this might be right for
Endometrial Cancer
Faeth Therapeutics 40
Testing effectiveness (Phase 2)Ended earlyNCT02644122
What this trial is testing

SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Ezra Cohen 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT04524000
What this trial is testing

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 24
Large-scale testing (Phase 3)Looking for participantsNCT02945033
What this trial is testing

Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk

Who this might be right for
Colorectal Cancer
University Hospital, Rouen 264
Early research (Phase 1)Not Yet RecruitingNCT07383506
What this trial is testing

Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Who this might be right for
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial Cancer+2 more
Cogent Biosciences, Inc. 90
Large-scale testing (Phase 3)Study completedNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439149
What this trial is testing

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Study completedNCT01307631
What this trial is testing

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell Adenocarcinoma+2 more
National Cancer Institute (NCI) 37
Not applicableStudy completedNCT04976439
What this trial is testing

Patogenic Mutation in 5 Genes

Who this might be right for
Colorectal CancerAPC Gene MutationTP53 Gene Mutation+3 more
Dr Cipto Mangunkusumo General Hospital 22
Early research (Phase 1)Ended earlyNCT02476955
What this trial is testing

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Who this might be right for
Solid TumorsOvarian CancerEndometrial Cancer
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Not applicableStudy completedNCT00898898
What this trial is testing

Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831

Who this might be right for
Breast Cancer
Alliance for Clinical Trials in Oncology 2,837
Early research (Phase 1)Not Yet RecruitingNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Early research (Phase 1)Looking for participantsNCT06239467
What this trial is testing

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Who this might be right for
Advanced CancerBreast CancerAdvanced Solid Tumors+1 more
OnKure, Inc. 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439175
What this trial is testing

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 70
Early research (Phase 1)Active Not RecruitingNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Early research (Phase 1)Study completedNCT05759949
What this trial is testing

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+5 more
Relay Therapeutics, Inc. 41
Load More Results